Protara Therapeutics (TARA) Competitors

Protara Therapeutics (NASDAQ:TARA) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Do analysts recommend TARA or ETON?

Protara Therapeutics presently has a consensus target price of $22.67, suggesting a potential upside of 403.70%. Eton Pharmaceuticals has a consensus target price of $24.00, suggesting a potential upside of 38.65%. Given Protara Therapeutics' higher probable upside, equities analysts clearly believe Protara Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Eton Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Which has more volatility and risk, TARA or ETON?

Protara Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Does the MarketBeat Community prefer TARA or ETON?

Eton Pharmaceuticals received 59 more outperform votes than Protara Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Protara Therapeutics an outperform vote while only 65.07% of users gave Eton Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Protara Therapeutics	Outperform Votes 36 66.67%	Underperform Votes 18 33.33%
Eton Pharmaceuticals	Outperform Votes 95 65.07%	Underperform Votes 51 34.93%

Do insiders and institutionals hold more shares of TARA or ETON?

38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 12.5% of Protara Therapeutics shares are held by company insiders. Comparatively, 14.9% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Does the media refer more to TARA or ETON?

In the previous week, Eton Pharmaceuticals had 19 more articles in the media than Protara Therapeutics. MarketBeat recorded 21 mentions for Eton Pharmaceuticals and 2 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.87 beat Eton Pharmaceuticals' score of 0.58 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Protara Therapeutics	Very Positive
Eton Pharmaceuticals	Positive

Is TARA or ETON more profitable?

Protara Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -15.81%. Eton Pharmaceuticals' return on equity of -36.29% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-55.96%	-49.06%
Eton Pharmaceuticals	-15.81%	-36.29%	-16.84%

Which has better earnings & valuation, TARA or ETON?

Eton Pharmaceuticals has higher revenue and earnings than Protara Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$40.42M	-$2.82	-1.60
Eton Pharmaceuticals	$31.64M	14.25	-$940K	-$0.22	-78.68

Summary

Eton Pharmaceuticals beats Protara Therapeutics on 10 of the 18 factors compared between the two stocks.